OBJECTIVE: To evaluate the efficacy

safety and economy of roxadustat in the treatment of renal anemia by rapid health technology

and to provide evidence-based evidence for clinical rational drug use. METHODS: The Cochrane Library

PubMed

CNKI and Wanfang Data were retrieved to collect the health technology assessment report

systematic evaluation/Meta-analysis and pharmacoeconomic study related to roxadustat in the treatment of renal anemia

the search time was from the establishment of the database to Oct. 2021. Two reviewers independently screened the literature according to the inclusion and exclusion criteria

evaluated the quality of the literature

and analyzed the literature. RESULTS: Totally 11 systematic reviews/Meta-analysis and 2 pharmacoeconomic studies were included. In terms of efficacy

compared with placebo or control drugs

roxadustat could significantly increase the hemoglobin level and total iron binding capacity and decrease the hepcidin level in patients with renal anemia. In terms of safety

there was no significant increase in adverse events and severe adverse events in patients treated with roxadustat

yet the incidence of hyperkalemia was significantly higher than that in the placebo group. Economically

there was a cost-utility advantage to roxadustat for non-dialysis renal anemia patients. CONCLUSIONS: Rosarostat is effective and economical in the treatment of renal anemia

and care should be taken to monitor the serum potassium ion concentration.